<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03442972</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-2 Biopsy 16-6368</org_study_id>
    <nct_id>NCT03442972</nct_id>
  </id_info>
  <brief_title>Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids</brief_title>
  <acronym>GLP-2 Biopsy</acronym>
  <official_title>Investigating the Release of Stored Enteral Lipids in Response to a Single Subcutaneous Dose of Analogue Glucagon-like Peptide-2 in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kensington Screening Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This
      triglyceride can then be released into the blood when another meal is consumed or in response
      to hormones. How the gut hormone glucagon-like peptide-2 (GLP-2) releases the triglyceride
      from the gut is not known. The research team in this study is interested in finding out how
      teduglutide (a degradation resistant form of GLP-2) releases stored triglyceride from the gut
      by studying samples from patients undergoing endoscopy and small bowel biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The release of stored enteral lipids will be investigated in 30 patients undergoing upper
      gastrointestinal endoscopy and duodenal biopsy for clinical indications. Patients undergoing
      the procedure will be recruited. Participants will have a high fat liquid meal as breakfast.
      5 hours later, participants will be randomly assigned to receive either a subcutaneous
      injection of placebo (n=15) or a subcutaneous injection of the Health Canada approved
      glucagon-like peptide-2 (GLP-2) analogue (teduglutide, REVESTIVE®, Shire Canada)(n=15
      different subjects). 1 hour later, a duodenal biopsy specimen will be obtained from 2-3
      sample sites,snap frozen in dry ice and stored at -80°C for further analysis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to receive either teduglutide or placebo as a single subcutaneous injection, 1 hour prior to duodenal biopsy</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-blinded study with participant blinded to treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Release of enteral lipids in response to teduglutide</measure>
    <time_frame>6 hours</time_frame>
    <description>To quantify the difference in amount of enteral lipids between GLP-2 and placebo treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Teduglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teduglutide, up to 0.05mg/kg, subcutaneous, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, subcutaneous, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>Teduglutide</description>
    <arm_group_label>Teduglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, aged 18 to 60 years requiring endoscopy and duodenal biopsies for
             clinical indications, with no contraindications to the procedure, as judged by Dr.
             Bookman of the Kensington Screening Clinic, Toronto, ON, Canada

        Exclusion Criteria:

          -  Patients with active inflammatory bowel disease

          -  Patients with pre-existing Celiac disease, exocrine pancreatic insufficiency or small
             bowel malabsorption

          -  Patients with active bowel malignancy

          -  Patients with diabetes mellitus or known/ suspected motility disorders of the gut

          -  Patients with decompensated liver disease

          -  Patients on ezetimibe or bile acid sequestrants

          -  Patients who are pregnant or breastfeeding.

          -  Patients with renal disease

          -  Patients on benzodiazepine

          -  Unstable cardiac or respiratory disease

          -  Any changes to medication in the preceding month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UHN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brenda Hughes, RN</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>8886</phone_ext>
    <email>brenda.hughes@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toronto General Hopital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kensington Screening Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Bookman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intestinal lipoprotein</keyword>
  <keyword>Duodenal biopsy</keyword>
  <keyword>Gut Peptide</keyword>
  <keyword>Chylomicrons</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

